These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
173 related articles for article (PubMed ID: 36319752)
1. An Fc variant with two mutations confers prolonged serum half-life and enhanced effector functions on IgG antibodies. Ko S; Park S; Sohn MH; Jo M; Ko BJ; Na JH; Yoo H; Jeong AL; Ha K; Woo JR; Lim C; Shin JH; Lee D; Choi SY; Jung ST Exp Mol Med; 2022 Nov; 54(11):1850-1861. PubMed ID: 36319752 [TBL] [Abstract][Full Text] [Related]
2. Antibody Fc engineering for enhanced neonatal Fc receptor binding and prolonged circulation half-life. Mackness BC; Jaworski JA; Boudanova E; Park A; Valente D; Mauriac C; Pasquier O; Schmidt T; Kabiri M; Kandira A; Radošević K; Qiu H MAbs; 2019 Oct; 11(7):1276-1288. PubMed ID: 31216930 [TBL] [Abstract][Full Text] [Related]
3. Combined glyco- and protein-Fc engineering simultaneously enhance cytotoxicity and half-life of a therapeutic antibody. Monnet C; Jorieux S; Souyris N; Zaki O; Jacquet A; Fournier N; Crozet F; de Romeuf C; Bouayadi K; Urbain R; Behrens CK; Mondon P; Fontayne A MAbs; 2014; 6(2):422-36. PubMed ID: 24492301 [TBL] [Abstract][Full Text] [Related]
4. Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). Dall'Acqua WF; Kiener PA; Wu H J Biol Chem; 2006 Aug; 281(33):23514-24. PubMed ID: 16793771 [TBL] [Abstract][Full Text] [Related]
5. Humanized FcRn mouse models for evaluating pharmacokinetics of human IgG antibodies. Proetzel G; Roopenian DC Methods; 2014 Jan; 65(1):148-53. PubMed ID: 23867339 [TBL] [Abstract][Full Text] [Related]
6. Recent Achievements and Challenges in Prolonging the Serum Half-Lives of Therapeutic IgG Antibodies Through Fc Engineering. Ko S; Jo M; Jung ST BioDrugs; 2021 Mar; 35(2):147-157. PubMed ID: 33608823 [TBL] [Abstract][Full Text] [Related]
8. Monoclonal antibody clearance. Impact of modulating the interaction of IgG with the neonatal Fc receptor. Datta-Mannan A; Witcher DR; Tang Y; Watkins J; Wroblewski VJ J Biol Chem; 2007 Jan; 282(3):1709-17. PubMed ID: 17135257 [TBL] [Abstract][Full Text] [Related]
9. An "Fc-Silenced" IgG1 Format With Extended Half-Life Designed for Improved Stability. Borrok MJ; Mody N; Lu X; Kuhn ML; Wu H; Dall'Acqua WF; Tsui P J Pharm Sci; 2017 Apr; 106(4):1008-1017. PubMed ID: 28057542 [TBL] [Abstract][Full Text] [Related]
10. Conformational Destabilization of Immunoglobulin G Increases the Low pH Binding Affinity with the Neonatal Fc Receptor. Walters BT; Jensen PF; Larraillet V; Lin K; Patapoff T; Schlothauer T; Rand KD; Zhang J J Biol Chem; 2016 Jan; 291(4):1817-1825. PubMed ID: 26627822 [TBL] [Abstract][Full Text] [Related]
11. Global conformational changes in IgG-Fc upon mutation of the FcRn-binding site are not associated with altered antibody-dependent effector functions. Burvenich IJG; Farrugia W; Liu Z; Makris D; King D; Gloria B; Perani A; Allan LC; Scott AM; Ramsland PA Biochem J; 2018 Jul; 475(13):2179-2190. PubMed ID: 29794155 [TBL] [Abstract][Full Text] [Related]
12. Extending serum half-life of albumin by engineering neonatal Fc receptor (FcRn) binding. Andersen JT; Dalhus B; Viuff D; Ravn BT; Gunnarsen KS; Plumridge A; Bunting K; Antunes F; Williamson R; Athwal S; Allan E; Evans L; Bjørås M; Kjærulff S; Sleep D; Sandlie I; Cameron J J Biol Chem; 2014 May; 289(19):13492-502. PubMed ID: 24652290 [TBL] [Abstract][Full Text] [Related]
13. Fc engineered anti-virus therapeutic human IgG Park SA; Lee Y; Hwang H; Lee JH; Kang YJ; Kim Y; Jin C; An HJ; Oh YJ; Hinterdorfer P; Kim E; Choi S; Ko K Biotechnol J; 2024 Mar; 19(3):e2300552. PubMed ID: 38528347 [TBL] [Abstract][Full Text] [Related]
14. The neonatal Fc receptor (FcRn) binds independently to both sites of the IgG homodimer with identical affinity. Abdiche YN; Yeung YA; Chaparro-Riggers J; Barman I; Strop P; Chin SM; Pham A; Bolton G; McDonough D; Lindquist K; Pons J; Rajpal A MAbs; 2015; 7(2):331-43. PubMed ID: 25658443 [TBL] [Abstract][Full Text] [Related]
15. Characterization and screening of IgG binding to the neonatal Fc receptor. Neuber T; Frese K; Jaehrling J; Jäger S; Daubert D; Felderer K; Linnemann M; Höhne A; Kaden S; Kölln J; Tiller T; Brocks B; Ostendorp R; Pabst S MAbs; 2014; 6(4):928-42. PubMed ID: 24802048 [TBL] [Abstract][Full Text] [Related]
16. pH-dependent binding engineering reveals an FcRn affinity threshold that governs IgG recycling. Borrok MJ; Wu Y; Beyaz N; Yu XQ; Oganesyan V; Dall'Acqua WF; Tsui P J Biol Chem; 2015 Feb; 290(7):4282-90. PubMed ID: 25538249 [TBL] [Abstract][Full Text] [Related]
17. Improved in vivo anti-tumor effects of IgA-Her2 antibodies through half-life extension and serum exposure enhancement by FcRn targeting. Meyer S; Nederend M; Jansen JH; Reiding KR; Jacobino SR; Meeldijk J; Bovenschen N; Wuhrer M; Valerius T; Ubink R; Boross P; Rouwendal G; Leusen JH MAbs; 2016; 8(1):87-98. PubMed ID: 26466856 [TBL] [Abstract][Full Text] [Related]
18. A novel in vitro assay to predict neonatal Fc receptor-mediated human IgG half-life. Souders CA; Nelson SC; Wang Y; Crowley AR; Klempner MS; Thomas W MAbs; 2015; 7(5):912-21. PubMed ID: 26018774 [TBL] [Abstract][Full Text] [Related]
19. Neonatal Fc receptor (FcRn): a novel target for therapeutic antibodies and antibody engineering. Wang Y; Tian Z; Thirumalai D; Zhang X J Drug Target; 2014 May; 22(4):269-78. PubMed ID: 24404896 [TBL] [Abstract][Full Text] [Related]
20. Structural characterization of a human Fc fragment engineered for extended serum half-life. Oganesyan V; Damschroder MM; Woods RM; Cook KE; Wu H; Dall'acqua WF Mol Immunol; 2009 May; 46(8-9):1750-5. PubMed ID: 19250681 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]